WELL:LSE:LSE-Hanetf Icav - Han-Gins Healthcare Innovation Ucits ETF (USD)

ETF | Others |

Last Closing

USD 7.4605

Change

0.00 (0.00)%

Market Cap

N/A

Volume

261.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-28 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 572.76B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 572.76B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B
0QZO:LSE 0QZO

N/A

USD 258.54B
0QZ3:LSE Qualcomm Inc.

N/A

USD 202.26B
PRJU:LSE Amundi Index Solutions - Amund..

N/A

USD 200.79B
0R24:LSE Intel Corp.

N/A

USD 196.14B

ETFs Containing WELL:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.72% 25% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.72% 25% F 35% F
Trailing 12 Months  
Capital Gain 12.80% 45% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.80% 45% F 50% F
Trailing 5 Years  
Capital Gain -1.31% 27% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.31% 27% F 38% F
Average Annual (5 Year Horizon)  
Capital Gain -2.65% N/A N/A 28% F
Dividend Return -2.65% N/A N/A 27% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 23.15% N/A N/A 41% F
Risk Adjusted Return -11.45% N/A N/A 30% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike